bioRxiv Science⌕ Search

Biology subjects

Negron, N.

Publications and source records attributed to Negron, N..

3 recordsLinked to original sources

Optimizing murine sample sizes for RNA-seq studies revealed from large-scale comparative analysis

Determining the appropriate sample size (N) for comparative biological experiments is critical for obtaining reliable results. In order to determine the N, the usual approach is to perform a power calculation, which involves understanding the variability between samples and the expected effect size. Here, we focused on bulk RNA-seq experiments, which have become ubiquitous in biology, but which have many unknown or difficult to estimate parameters, and so the required analyses to determine the minimum N is typically lacking. We therefore performed two N=30 profiling studies between wild-type mice and mice in which one copy of a gene had been deleted, to determine how many mice would be required to minimize false positives and to maximize true discoveries found in the N of 30 experiment. Results from experiments with N=4 or less are shown to be highly misleading, given the substantial false positive rate, and the lack of discovery of genes later found with higher N. For a cut-off of 2-fold expression differences, we found that an N of 6-7 mice was required to consistently decrease the false positive rate to below 50%, and that "more is always better" when it came to discovery rates - an N of 8-12 is significantly better in lowering the false positive rate. A common method to reduce false discovery rate in underpowered experiments is to raise the fold cutoff or increase the stringency of the P-value and include only highly perturbed, highly significant genes. We show that while this strategy is no substitute for increasing the N of the experiment, because it results in consistently inflated effect sizes and a substantial drop in sensitivity. These data should be helpful to others in choosing their Ns, since its often not practical to do such large studies for every mouse model.

bioinformatics↗

In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. As rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of minor virus variants in SARS-COV-2 isolates found in COVID-19 patients or identified from preclinical in vitro and in vivo studies. This study demonstrates that a combination of non-competing antibodies, REGEN-COV, not only provides full coverage against current variants of concern/interest but also protects against emergence of new such variants and their potential seeding into the population in a clinical setting.

microbiology↗

REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters

An urgent global quest for effective therapies to prevent and treat COVID-19 disease is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987+REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques and golden hamsters and demonstrate that REGN-COV-2 can greatly reduce virus load in lower and upper airway and decrease virus induced pathological sequalae when administered prophylactically or therapeutically. Our results provide evidence of the therapeutic potential of this antibody cocktail.

microbiology↗